Obicetrapib Wins First CETP Approval, But Outcomes Gap Clouds Payer Path

European Commission Approves Ubeslo and Evlarco for Hypercholesterolaemia

NewAmsterdam Pharma and its partner Menarini Group announced that the European Commission (EC) has granted marketing authorization for Ubeslo® (obicetrapib 10 mg monotherapy) and Evlarco® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination). This approval is for patients with primary hypercholesterolaemia, including heterozygous familial (HeFH) and non-familial or mixed dyslipidaemia, marking the first global regulatory approval for obicetrapib. The decision is supported by data from Phase 3 BROADWAY, BROOKLYN, and TANDEM trials, which demonstrated significant LDL-C reductions and a favorable tolerability profile.

• The European Commission's approval of Ubeslo and Evlarco represents a significant global milestone for NewAmsterdam Pharma, marking the first regulatory authorization for obicetrapib. This novel oral therapy is poised to expand treatment options for patients struggling to achieve recommended LDL-C levels despite existing therapies, addressing a substantial unmet need in cardiovascular medicine.
• The approval is underpinned by robust clinical evidence from NewAmsterdam's comprehensive development program, including the Phase 3 BROADWAY, BROOKLYN, and TANDEM trials. These studies demonstrated statistically significant LDL-C reductions of up to 40% with obicetrapib monotherapy and approximately 50% with obicetrapib combined with ezetimibe, both showing a tolerability profile comparable to placebo.
• Under the licensing agreement, Menarini Group holds exclusive commercialization rights for obicetrapib in Europe, covering both monotherapy and fixed-dose combination. NewAmsterdam Pharma is entitled to tiered double-digit percentage royalties on net sales in the Menarini Territory, ranging from low double-digits to mid-twenties, and is eligible for up to an additional €833 million upon achieving various clinical, regulatory, and commercial milestones.

BROADWAY, BROOKLYN, and TANDEM: Key Data Behind EC Approval

Recent clinical evidence across multiple study designs — randomised controlled trials, phase 2 and 4 studies, and real-world audits — continues to expand the evidence base for lipid-lowering interventions in primary hypercholesterolaemia. The studies below span novel oral agents, established injectable PCSK9 inhibitors, and an ATP-citrate lyase inhibitor, collectively illustrating the breadth of current therapeutic approaches.

Obicetrapib's Place in the Evolving Hypercholesterolaemia Landscape

The pharmacological management of primary hypercholesterolaemia has undergone meaningful expansion over the past several years, driven by the recognition that statins — while remaining the primary therapy for LDL-C reduction — are frequently insufficient to achieve increasingly aggressive LDL-C targets. Ezetimibe is the next recommended addition to statin therapy, with bempedoic acid emerging as a further oral option that can be added to or substituted for statins. Bempedoic acid, approved by the FDA in February 2020 and the EMA in March 2020, inhibits cholesterol biosynthesis via the same mechanistic pathway as statins but is hepatically converted to its active form without activation in skeletal muscle — a distinction that yields a lower prevalence of musculoskeletal-related adverse events and positions it as an alternative for statin-intolerant patients. In UK practice, a multicentre audit of 221 adults treated with bempedoic acid demonstrated that 54% (99/184) achieved the JBS2 audit standard at 12 weeks post-initiation, with a mean percentage LDL-C reduction from baseline of 22.0%.

Injectable PCSK9 inhibitors — alirocumab and evolocumab — represent the most effective currently available agents for LDL-C reduction, yet their uptake has not met expectations due to cost and patients' reluctance to accept injection therapy. In patients with diabetes and dyslipidaemia specifically, a meta-analysis of eight randomised controlled trials enrolling 20,651 patients found that PCSK9 inhibitor use reduced major cardiovascular events (MACE) by 18% (OR: 0.82; 95% CI: 0.74–0.90) and produced a mean LDL-C reduction of -58.48% (95% CI: -63.73 to -53.22%, P < 0.0001) versus placebo. The siRNA agent inclisiran offers a mechanistically distinct approach, targeting hepatic PCSK9 messenger RNA to deliver sustained LDL-C reduction with a twice-yearly dosing schedule. In the VICTORION-Difference phase 4 trial, an inclisiran-based strategy achieved individual LDL-C goals in 84.9% of participants at Day 90 versus 31.0% with individually optimised lipid-lowering therapy (OR 12.09, p<0.001), with a mean LDL-C reduction of -59.5% from baseline to Day 360 and fewer muscle-related adverse events (11.9% vs. 19.2%; OR 0.57, p<0.001).

On the horizon, novel agents are poised to further reshape the landscape. Tafolecimab, a PCSK9 monoclonal antibody investigated in the CREDIT-1, CREDIT-2, and CREDIT-4 trials, has demonstrated significant LDL-C reduction and a favourable safety profile, with data suggesting greater affinity for PCSK9 and a longer duration of LDL-C reduction than evolocumab; its extended dosing interval may also enhance patient compliance and reduce treatment costs, though its long-term cardiovascular outcomes data remain to be fully elucidated. Oral PCSK9 inhibitors in development and obicetrapib have been characterised as appearing safe and very effective, with the potential — if approved — to provide useful alternatives for reaching LDL-C goals, though long-term adherence to therapy is expected to remain a challenge across the treatment class.

The CETP Inhibitor Landscape: Obicetrapib's First-in-Class Position

Several CETP inhibitors have been investigated for dyslipidemia — the same indication and mechanism of action as obicetrapib — with varying outcomes across their clinical development programs. Three agents in particular — anacetrapib, dalcetrapib, and evacetrapib — have been evaluated in randomized controlled trials, though not all programs reached completion.

The knowledge base does not have sufficient information on this aspect.

Obicetrapib's European Debut: A New Era for CETP Inhibition

The European Commission's marketing authorization for obicetrapib, both as a monotherapy (Ubeslo®) and in a fixed-dose combination with ezetimibe (Evlarco®), marks a pivotal moment in dyslipidemia management. This represents the first global regulatory approval for a cholesteryl ester transfer protein (CETP) inhibitor, a class of drugs with a complex development history. Previous attempts with CETP inhibitors faced significant safety concerns, notably torcetrapib, which increased cardiovascular events. Obicetrapib, however, has demonstrated a favorable tolerability profile alongside significant reductions in low-density lipoprotein cholesterol (LDL-C) in trials like BROADWAY, BROOKLYN, and TANDEM.

This approval provides a much-needed oral therapeutic option for patients with primary hypercholesterolaemia, including those with heterozygous familial hypercholesterolaemia (HeFH) and mixed dyslipidaemia, who often struggle to achieve target LDL-C levels with existing maximally tolerated lipid-modifying therapies. The fixed-dose combination with ezetimibe is particularly compelling, offering a dual mechanism of action—CETP inhibition and cholesterol absorption blockade—leading to even greater LDL-C reductions. Studies have shown this combination can achieve remarkable LDL-C reductions, with a high proportion of patients reaching aggressive lipid goals.

However, the journey for obicetrapib is not without its considerations. While lipid-lowering efficacy is clear, the ultimate impact on long-term cardiovascular outcomes, a critical benchmark, is still awaiting definitive data from ongoing trials. The market is also increasingly crowded with other highly effective non-statin therapies, including PCSK9 inhibitors, which have robust cardiovascular outcome data.

Intriguingly, recent research suggests obicetrapib may offer benefits beyond lipid management. A substudy of the BROADWAY trial indicated that obicetrapib significantly attenuated increases in Alzheimer's disease (AD) biomarkers, such as p-tau217, especially in ApoE4 carriers. This finding opens a fascinating potential avenue for AD prevention, particularly for a high-risk population currently lacking effective options. While these biomarker changes are promising, their translation into clinical benefits in dedicated AD prevention trials remains to be established. This dual promise—potent lipid lowering and potential neuroprotective effects—positions obicetrapib as a drug with broader strategic implications.